
Noreen Roth Henig MD
Critical Care Medicine
Sr. Director, Cardiopulmonary Medical Affairs
Join to View Full Profile
2351 Clay St#501San Francisco, CA 94115
Phone+1 415-923-3421
Fax+1 415-600-1414
Dr. Henig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1998
University of California (San Francisco)Residency, Internal Medicine, 1992 - 1995
Albert Einstein College of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1994 - 2028
Clinical Trials
- Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Start of enrollment: 2020 Mar 12
Publications & Presentations
PubMed
- 45 citationsAntisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosisPavel Drevinek, Tacjana Pressler, Marco Cipolli, Kris De Boeck, Carsten Schwarz
Journal of Cystic Fibrosis. 2020-01-01 - 43 citationsAntisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P. Clancy, David P. Nichols, Jerry A. Nick, Kris De Boeck
Journal of Cystic Fibrosis. 2019-07-01 - 116 citationsPulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restrictionGanesh Raghu, Steven D. Nathan, Juergen Behr, Kevin K. Brown, Jim J. Egan
The European Respiratory Journal. 2015-08-06
Press Mentions
Oral Heart Failure Drug Receives FDA’s Fast Track DesignationNovember 20th, 2025
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 1st, 2023
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus NephritisJune 27th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









